2025
1109-P: Physician Referral Pathway to a Commercially Marketed Digital Exercise Resource for Type 1 Diabetes—Implementation Metrics from a Clinical Trial
ASH G, MAK S, (ELIAS) SPANAKIS I, LUKASIK J, NALLY L, FUCITO L, WEINZIMER S. 1109-P: Physician Referral Pathway to a Commercially Marketed Digital Exercise Resource for Type 1 Diabetes—Implementation Metrics from a Clinical Trial. Diabetes 2025, 74 DOI: 10.2337/db25-1109-p.Peer-Reviewed Original ResearchPrimary care providersHome-based exerciseExercise prescriptionReferral pathwaysParticipating primary care providersPCP responsesClinical trial participationExercise intensityCare providersTrials of participantsCoach appVigorous exerciseNon-HispanicEligible participantsPortal messagesClinical trials of participantsLatent autoimmune diabetes of adulthoodModerate exerciseHealthcare systemTrial participantsSnowball samplingExercisePain symptomsClinical trialsUncontrolled hypertension1904-LB: Usability and Acceptability of a Biometric Dashboard with Tailored Coaching Tips for Exercise by Adults with Type 1 Diabetes
ASH G, NALLY L, LUKASIK J, MAK S, GRIGGS S, (ELIAS) SPANAKIS I, FUCITO L, WEINZIMER S. 1904-LB: Usability and Acceptability of a Biometric Dashboard with Tailored Coaching Tips for Exercise by Adults with Type 1 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-1904-lb.Peer-Reviewed Original ResearchSystem Usability ScaleIntervention appropriateType 1 diabetesTreatment satisfaction surveyExercise guidelinesImplementation outcomesTelehealth coachingOverall interventionCompared to V1Satisfaction surveyMotivational supportCoaches insightAdult participantsMann-Whitney U testUsability ScaleOverall satisfactionPromoter ScoreInterventionCoachingExerciseUsability enhancementsSatisfactionUser satisfactionEfficacy trialsGlycemic changesDifferences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow-up: Relation to Dysglycemia.
Mauras N, Ma Q, Weinzimer S, White N, Tsalikian E, Buckingham B, Fox L, Tamborlane W, Arbelaez A, Tansey M, Aye T, Cato A, Hershey T, Englert K, Marzelli M, Jo B, Reiss A. Differences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow-up: Relation to Dysglycemia. Diabetes 2025 PMID: 40455934, DOI: 10.2337/db24-0684.Peer-Reviewed Original ResearchWhite matter microstructureType 1 diabetesWhite matter myelinationControl participantsCognitive AssessmentFractional anisotropyLongitudinal studyAxial diffusivityLongitudinal Follow-upImpact of chronic hyperglycemiaYoung childrenFiber integrityWhite matterBrainChildrenBrain MRIChronic hyperglycemiaTime pointsContinuous glucose monitoringControl groupDiabetesDetrimental effectsHyperglycemiaParticipantsGlucose monitoring“Can I afford to live today?” The emotional toll of navigating the healthcare system with type 1 diabetes
Harel S, Lukasik J, Wilcox A, Lipska K, Weinzimer S, Suttiratana S, Nally L. “Can I afford to live today?” The emotional toll of navigating the healthcare system with type 1 diabetes. Frontiers In Endocrinology 2025, 16: 1555265. PMID: 40196455, PMCID: PMC11973976, DOI: 10.3389/fendo.2025.1555265.Peer-Reviewed Original ResearchConceptsHealthcare systemDiabetes managementBurden of managing diabetesType 1 diabetesSelf-reported useTranscripts of semi-structuredFeelings of powerlessnessQuality of lifeFear of health problemsDaily diabetes managementDefinition of themesDiabetes supportStudy of individualsChild healthDiabetes suppliesTelephone interviewsDiabetes medicationsEmotional tollSemi-structuredHealth problemsFinancial burdenHealthcarePWDParticipantsDiabetes
2024
Personal and Social‐Built Environmental Factors of Glucose Variability Among Multiethnic Groups of Adults With Type 2 Diabetes: Research Protocol Using Ecological Momentary Assessment, Continuous Glucose Monitoring, and Actigraphy
Nam S, Jeon S, Ash G, Weinzimer S, Dunton G, Parekh N, Grey M, Chen K, Lee M, Sajdlowska A, Whittemore R. Personal and Social‐Built Environmental Factors of Glucose Variability Among Multiethnic Groups of Adults With Type 2 Diabetes: Research Protocol Using Ecological Momentary Assessment, Continuous Glucose Monitoring, and Actigraphy. Research In Nursing & Health 2024, 47: 608-619. PMID: 39243147, PMCID: PMC11934073, DOI: 10.1002/nur.22420.Peer-Reviewed Original ResearchEmotional Well-BeingType 2 diabetesImprove diabetes outcomesDietary recall dataWell-beingSelf-report toolMultilevel risk factorsEcological momentary assessmentLifestyle behaviorsOnline video callsContinuous glucose monitoringPhysical activityDiabetes outcomesGroup of adultsLifestyle factorsJust-in-time interventionsBaseline surveyDiverse adultsDiabetes InterventionsHigh-risk groupRecall dataMomentary assessmentActigraphy deviceStructural equation modelingGlucose monitoringCost-Effectiveness of Closed-Loop Automated Insulin Delivery Using the Cambridge Hybrid Algorithm in Children and Adolescents With Type 1 Diabetes: Results from a Multicenter 6-Month Randomized Trial
Fox D, Ware J, Boughton C, Allen J, Wilinska M, Tauschmann M, Denvir L, Thankamony A, Campbell F, Wadwa R, Buckingham B, Davis N, DiMeglio L, Mauras N, Besser R, Ghatak A, Weinzimer S, Kanapka L, Kollman C, Sibayan J, Beck R, Hood K, Hovorka R. Cost-Effectiveness of Closed-Loop Automated Insulin Delivery Using the Cambridge Hybrid Algorithm in Children and Adolescents With Type 1 Diabetes: Results from a Multicenter 6-Month Randomized Trial. Journal Of Diabetes Science And Technology 2024, 19: 982-991. PMID: 38494876, PMCID: PMC11571777, DOI: 10.1177/19322968241231950.Peer-Reviewed Original ResearchQuality-adjusted life yearsType 1 diabetesDiabetic ketoacidosisClosed-loop automated insulin deliveryDiscounted quality-adjusted life yearsTreatment groupsContinuous glucose monitoringIncremental cost-effectivenessParallel controlled trialProbabilistic sensitivity analysesInsulin deliveryInsulin pump therapyLifetime cost-effectivenessContemporaneous control groupUsual careImproved HbA<sub>1c</sub>Participants aged 6Health-related quality of lifeAutomated Insulin DeliverySubgroup patientsTreatment subgroupsSevere hypoglycemiaRandomized trialsTotal health care utilizationLifetime complications
2023
Real-World Diabetes Technology: Overcoming Barriers and Disparities
Messer L, Addala A, Weinzimer S. Real-World Diabetes Technology: Overcoming Barriers and Disparities. Diabetes Technology & Therapeutics 2023, 25: s-176-s-190. PMID: 36802191, DOI: 10.1089/dia.2023.2511.Peer-Reviewed Original ResearchPersonalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes
Ash G, Nally L, Stults-Kolehmainen M, De Los Santos M, Jeon S, Brandt C, Gulanski B, Spanakis E, Baker J, Weinzimer S, Fucito L. Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes. Clinical Journal Of Sport Medicine 2023, 33: 512-520. PMID: 36715983, PMCID: PMC10898917, DOI: 10.1097/jsm.0000000000001078.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringExercise supportHealth informationDigital health informationBody mass indexType 1 diabetesCommunity-based sampleSevere hypoglycemiaMass indexPsychosocial assessmentCGM useHigh satisfaction ratingsPhysician oversightType 1Future interventionsGlucose monitoringMedical readinessMolecular biomarkersBaseline observationsInterventionSatisfaction ratingsAdultsExerciseBehavioral skillsSingle group
2022
Navigating barriers to affording and obtaining insulin and diabetes supplies
Wilcox A, Lipska K, Weinzimer S, Gujral J, Arakaki A, Kerandi L, Nally L. Navigating barriers to affording and obtaining insulin and diabetes supplies. Journal Of Diabetes 2022, 15: 71-75. PMID: 36562281, PMCID: PMC9870729, DOI: 10.1111/1753-0407.13344.Peer-Reviewed Original Research“It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes
Hughes A, Chapman K, Bispham J, Dimsits J, Weinzimer S, Wolf W, Heydarian N. “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes. Journal Of Clinical & Translational Endocrinology 2022, 30: 100310. PMID: 36620758, PMCID: PMC9816066, DOI: 10.1016/j.jcte.2022.100310.Peer-Reviewed Original ResearchSevere hypoglycemiaType 1 diabetesGlucagon useMini-dose glucagonEase of administrationPrescription costsNasal administrationEmergency treatmentGlucagon actionPerspectives of adultsHypoglycemiaDiabetesGlucagon treatmentHealthcare professionalsGlucagonAverage durationPerspectives of peopleAdministrationAdultsParticipantsFocus groupsTreatmentCurrent studyFocus group interviewsEmotional impactDKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice
Doyle EA, Weinzimer SA, Tamborlane W. DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice. The Science Of Diabetes Self-Management And Care 2022, 48: 476-482. PMID: 36129121, DOI: 10.1177/26350106221125699.Peer-Reviewed Original ResearchConceptsContinuous glucose monitorHigher A1C levelsA1c levelsDKA eventsInsulin pumpPump usersPump-treated patientsRetrospective chart reviewPediatric endocrinology practiceType 1 diabetesInsulin pump usersConcurrent illnessDKA preventionPump patientsDiabetes durationDKA episodesMean A1CChart reviewEndocrinology practiceDKA ratesDKA severityMean ageInsulin omissionMost episodesPatientsConsensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O’Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews 2022, 44: 254-280. PMID: 36066457, PMCID: PMC9985411, DOI: 10.1210/endrev/bnac022.Peer-Reviewed Original ResearchConceptsInsulin delivery technologiesGlycemic goalsNear-normal glucose levelsLong-term complicationsReal-world studyHypoglycemia riskDiabetes QualityConsensus recommendationsGlucose levelsGlobal prevalenceDiabetes managementEligibility criteriaClinical practiceDelivery technologiesHealthcare providersClinical settingDiabetesInsurance coverageSignificant proportionCliniciansAid successPWDPayersComplicationsTremendous advancesAssessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults
Commissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.Peer-Reviewed Original ResearchConceptsYoung adultsTreatment surveyDiabetes device useLess diabetes distressCross-sectional studyType 1 diabetesQuality of lifeImpact of T1DInternal consistencyLower A1CMale sexDiabetes distressExcellent internal consistencyMedical recordsCGM useDiabetes managementT1DHealth outcomesDiabetesType 1Clinical interventionsPsychosocial outcomesBenefit findingA1CAdultsA Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes
Reiss AL, Jo B, Arbelaez AM, Tsalikian E, Buckingham B, Weinzimer SA, Fox LA, Cato A, White NH, Tansey M, Aye T, Tamborlane W, Englert K, Lum J, Mazaika P, Foland-Ross L, Marzelli M, Mauras N. A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes. Nature Communications 2022, 13: 4940. PMID: 36042217, PMCID: PMC9427757, DOI: 10.1038/s41467-022-32289-x.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemStandard care groupType 1 diabetesClosed-loop insulin delivery systemWhite matter volumeCare groupPrimary outcomeInsulin delivery systemsMatter volumeFractional anisotropyCognitive AssessmentRigorous glucose controlDiagnosis of T1DClosed-loop groupBetter diabetes controlDiabetes care groupsConcept pilot studyYears of ageAcademic medical centerFunctional brain activityCortical surface areaMonths study durationRandomized participantsDiabetes controlGlucose controlFeasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes
Deshpande S, Weinzimer SA, Gibbons K, Nally LM, Weyman K, Carria L, Zgorski M, Laffel LM, Doyle FJ, Dassau E. Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2022, 18: 363-371. PMID: 35971681, PMCID: PMC10973844, DOI: 10.1177/19322968221116384.Peer-Reviewed Original ResearchType 1 diabetesUnannounced exercisePercent timeGlucose standard deviationParents/guardiansSecondary outcomesAdverse eventsPrimary outcomeBlood glucose dataPump therapyPreliminary safetyAutomated Insulin DeliveryContinuous glucose monitoring dataPediatric participantsGlucose monitoring dataAge-based cohortsArtificial pancreas systemsLarge mealsInsulin deliveryGlucose dataYoung childrenDiabetesYounger cohortsChildrenCohortImpact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems
Dovc K, Battelino T, Beck RW, Sibayan J, Bailey RJ, Calhoun P, Turcotte C, Weinzimer S, Schweiger D, Nimri R, Bergenstal RM. Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems. Diabetes Technology & Therapeutics 2022, 24: 848-852. PMID: 35848991, PMCID: PMC9618368, DOI: 10.1089/dia.2022.0153.Peer-Reviewed Original ResearchLived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents
Hood KK, Garcia‐Willingham N, Hanes S, Tanenbaum ML, Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell F, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium T. Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obesity And Metabolism 2022, 24: 2309-2318. PMID: 35837984, PMCID: PMC9804666, DOI: 10.1111/dom.14815.Peer-Reviewed Original Research1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes
WILCOX A, MENCHER S, NALLY L, WEINZIMER S. 1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes. Diabetes 2022, 71 DOI: 10.2337/db22-1025-p.Peer-Reviewed Original ResearchNon-Hispanic whitesDiabetes distressAdverse short-term outcomesBurden of diabetesShort-term outcomesType 1 diabetesHigher HbA1cContinuous glucose monitorElevated hemoglobinHigh prevalenceHigh riskDiabetesREM groupEthnic groupsEthnic disparitiesInsulin pumpAdolescent SurveyType 1Group of adolescentsRacial disparitiesSpeakers bureauDiabetes technologyNovo NordiskGlucose monitorAdditional mediators619-P: Understanding Parental Influences on T1D Incorporation in Adolescents and Young Adults
COMMISSARIAT P, VOLKENING L, WEINZIMER S, DASSAU E, LAFFEL L. 619-P: Understanding Parental Influences on T1D Incorporation in Adolescents and Young Adults. Diabetes 2022, 71 DOI: 10.2337/db22-619-p.Peer-Reviewed Original ResearchCorrection to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families
Banerjee I, Raskin J, Arnoux JB, De Leon DD, Weinzimer SA, Hammer M, Kendall DM, Thornton PS. Correction to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families. Orphanet Journal Of Rare Diseases 2022, 17: 205. PMID: 35585549, PMCID: PMC9118786, DOI: 10.1186/s13023-022-02363-0.Peer-Reviewed Original ResearchBlood sugar levelsBlood sugarLow blood sugarCongenital hyperinsulinismTreatment optionsBrain damageRare diseaseUnmet needLow blood sugar levelsSugar levelsLimited treatment optionsAvailable treatment optionsSpecialized treatment centersBest possible treatmentPerspectives of patientsQuick referralNew medicationsHealthy personsNewborn babiesSide effectsAbnormal releaseBetter outcomesTreatment centersPossible treatmentDevelopmental delay
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply